Malignancies and cyclophosphamide exposure in Wegener's granulomatosis

Journal of Rheumatology

Volumn 35, Issue 1, 2008, Pages 11-13

  Bernatsky, Sasha ^a   Ramsey Goldman, Rosalind ^a   Clarke, Ann E ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACROLEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID; RITUXIMAB;

BLADDER CANCER; CANCER RISK; CLINICAL TRIAL; CYSTITIS; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED CANCER; DRUG INDUCED DISEASE; DRUG MEGADOSE; EDITORIAL; HUMAN; LEUKEMIA; LYMPHOMA; NEOPLASM; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN CANCER; TREATMENT DURATION; URINALYSIS; URINE CYTOLOGY; UTERINE CERVIX DYSPLASIA; WEGENER GRANULOMATOSIS;

ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; HUMANS; MUTAGENS; NEOPLASMS; RISK ASSESSMENT; WEGENER GRANULOMATOSIS;

EID: 38149012190     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (21)

1. Hoffman G, Kerr G, Leavitt R, et al. Wegener's granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Faurschou M, Sorensen I, Mellemkjaer L, et al. Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5.
3. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996;124:477-84.
4. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002;100:82-5.
5. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-45.
6. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 1987;83:1-9.
7. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997;40:2187-98.
8. Haubitz M, Schellong S, Gobel U, et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835-44.
9. Genereau T, Lortholary O, Leclerq P, et al. Treatment of systemic vasculitis with cyclophosphamide and steroids: daily oral low-dose cyclophosphamide administration after failure of a pulse intravenous high-dose regimen in four patients. Br J Rheumatol 1994;33:959-62.
10. Baecklund E, Backlin C, Iliadou A, et al. Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum 2006;54:3774-81.
11. Bernatsky S, Boivin JF, Joseph L, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis 2007; e-pub June 1.
12. Lovstrom B, Backlin C, Sundstrom C, Ekbom A, Lundberg IE. A closer look at non Hodgkin's lymphoma cases in a national Swedish systemic lupus erythematosus cohort - A nested case-control study. Ann Rheum Dis 2007; e-pub May 21.
13. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
14. Helfand M, Mahon SM, Eden KB, Frame PS, Orleans CT. Screening for skin cancer. Am J Prev Med 2001;20 Suppl:47-58.
15. Ognenovski VM, Marder W, Somers EC, et al. Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide. J Rheumatol 2004;31:1763-7.
16. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces Committee Opinion 152, March 1995). Obstet Gynecol 2003;102:417-27.
17. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. Curr Opin Rheumatol 2006;18:25-32.
18. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
19. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
20. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
21. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-83.